VIVOS INC Faces Going Concern Doubt, Secures $1.55M in Dilutive Offering Amidst FDA Setback

summarizeSummary

VIVOS INC's annual report reveals critical financial distress with a going concern warning and low cash, necessitating a recent $1.55 million dilutive offering. This comes alongside an FDA rejection for its human therapy product, despite strong growth in its animal therapy division.

check_boxKey Events

• Going Concern Warning Issued

  Independent auditors expressed substantial doubt about VIVOS INC's ability to continue as a going concern due to recurring losses and insufficient cash to cover operational obligations.

• Secured $1.55M in Dilutive Offering

  In March 2026, the company raised $1,553,000 through the sale of 19,200,000 common shares and 17,000,000 warrants, resulting in approximately 7.5% dilution based on current outstanding shares.

• FDA Rejects Human Therapy IDE

  The FDA rejected the Investigational Device Exemption (IDE) for the company's human therapy product, RadioGel, in August 2025, citing deficiencies. A resubmission is targeted for Q1/April 2026.

• Strong Growth in Animal Therapy Division

  The IsoPet animal therapy division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025 and aims to reach breakeven status in 2026.

auto_awesomeAnalysis

VIVOS INC's annual report highlights substantial doubt about its ability to continue as a going concern, citing recurring losses and insufficient cash ($1.56 million as of December 31, 2025). The company requires approximately $3.0 million annually for operations and $9.0 million over the next 36 months for critical FDA approval processes, clinical trials, and manufacturing expansion. To address these needs, VIVOS INC recently raised $1.55 million in March 2026 through a dilutive offering of 19.2 million common shares and 17 million warrants, representing approximately 7.5% dilution based on current outstanding shares. This follows an FDA rejection of its Investigational Device Exemption (IDE) for RadioGel in August 2025, a significant regulatory setback. Additionally, the company repriced 1.45 million warrants at a lower exercise price, increasing the likelihood of further dilution. Despite these financial and regulatory challenges, the company reported a 1,200% year-over-year increase in administered therapies for its IsoPet animal division and aims for breakeven in 2026. Investors should closely monitor the company's ability to secure additional funding, navigate the FDA pathway, and achieve profitability.